Literature DB >> 22496233

Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity.

Mark A Brockman1, Denis R Chopera, Alex Olvera, Chanson J Brumme, Jennifer Sela, Tristan J Markle, Eric Martin, Jonathan M Carlson, Anh Q Le, Rachel McGovern, Peter K Cheung, Anthony D Kelleher, Heiko Jessen, Martin Markowitz, Eric Rosenberg, Nicole Frahm, Jorge Sanchez, Simon Mallal, Mina John, P Richard Harrigan, David Heckerman, Christian Brander, Bruce D Walker, Zabrina L Brumme.   

Abstract

An attenuation of the HIV-1 replication capacity (RC) has been observed for immune-mediated escape mutations in Gag restricted by protective HLA alleles. However, the extent to which escape mutations affect other viral proteins during natural infection is not well understood. We generated recombinant viruses encoding plasma HIV-1 RNA integrase sequences from antiretroviral-naïve individuals with early (n = 88) and chronic (n = 304) infections and measured the in vitro RC of each. In contrast to data from previous studies of Gag, we observed little evidence that host HLA allele expression was associated with integrase RC. A modest negative correlation was observed between the number of HLA-B-associated integrase polymorphisms and RC in chronic infection (R = -0.2; P = 0.003); however, this effect was not driven by mutations restricted by protective HLA alleles. Notably, the integrase variants S119R, G163E, and I220L, which represent uncommon polymorphisms associated with HLA-C*05, -A*33, and -B*52, respectively, correlated with lower RC (all q < 0.2). We identified a novel C*05-restricted epitope (HTDNGSNF(114-121)) that likely contributes to the selection of the S119R variant, the polymorphism most significantly associated with lower RC in patient sequences. An NL4-3 mutant encoding the S119R polymorphism displayed a ~35%-reduced function that was rescued by a single compensatory mutation of A91E. Together, these data indicate that substantial HLA-driven attenuation of integrase is not a general phenomenon during HIV-1 adaptation to host immunity. However, uncommon polymorphisms selected by HLA alleles that are not conventionally regarded to be protective may be associated with impaired protein function. Vulnerable epitopes in integrase might therefore be considered for future vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22496233      PMCID: PMC3393549          DOI: 10.1128/JVI.07133-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope.

Authors:  Fred W Peyerl; Heidi S Bazick; Michael H Newberg; Dan H Barouch; Joseph Sodroski; Norman L Letvin
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 2.  Structural insights into the retroviral DNA integration apparatus.

Authors:  Peter Cherepanov; Goedele N Maertens; Stephen Hare
Journal:  Curr Opin Struct Biol       Date:  2011-02-01       Impact factor: 6.809

3.  Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters.

Authors:  Jaclyn K Wright; Zabrina L Brumme; Jonathan M Carlson; David Heckerman; Carl M Kadie; Chanson J Brumme; Bingxia Wang; Elena Losina; Toshiyuki Miura; Fundisiwe Chonco; Mary van der Stok; Zenele Mncube; Karen Bishop; Philip J R Goulder; Bruce D Walker; Mark A Brockman; Thumbi Ndung'u
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

Review 4.  Integrase inhibitors in the treatment of HIV-1 infection.

Authors:  William G Powderly
Journal:  J Antimicrob Chemother       Date:  2010-09-18       Impact factor: 5.790

Review 5.  Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.

Authors:  Bach-Yen T Nguyen; Robin D Isaacs; Hedy Teppler; Randi Y Leavitt; Peter Sklar; Marian Iwamoto; Larissa A Wenning; Michael D Miller; Joshua Chen; Ramon Kemp; Wei Xu; Robert A Fromtling; Joseph P Vacca; Steven D Young; Michael Rowley; Michael W Lower; Keith M Gottesdiener; Daria J Hazuda
Journal:  Ann N Y Acad Sci       Date:  2011-03       Impact factor: 5.691

6.  Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.

Authors:  Zabrina L Brumme; Chanson J Brumme; Celia Chui; Theresa Mo; Brian Wynhoven; Conan K Woods; Bethany M Henrick; Robert S Hogg; Julio S G Montaner; P Richard Harrigan
Journal:  J Infect Dis       Date:  2007-04-24       Impact factor: 5.226

7.  Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities.

Authors:  Nicole Frahm; B T Korber; C M Adams; J J Szinger; R Draenert; M M Addo; M E Feeney; K Yusim; K Sango; N V Brown; D SenGupta; A Piechocka-Trocha; T Simonis; F M Marincola; A G Wurcel; D R Stone; C J Russell; P Adolf; D Cohen; T Roach; A StJohn; A Khatri; K Davis; J Mullins; P J R Goulder; B D Walker; C Brander
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers.

Authors:  Zabrina L Brumme; Chun Li; Toshiyuki Miura; Jennifer Sela; Pamela C Rosato; Chanson J Brumme; Tristan J Markle; Eric Martin; Brian L Block; Alicja Trocha; Carl M Kadie; Todd M Allen; Florencia Pereyra; David Heckerman; Bruce D Walker; Mark A Brockman
Journal:  J Acquir Immune Defic Syndr       Date:  2011-02-01       Impact factor: 3.731

9.  Progression to AIDS in South Africa is associated with both reverting and compensatory viral mutations.

Authors:  Kuan-Hsiang Gary Huang; Dominique Goedhals; Jonathan M Carlson; Mark A Brockman; Swati Mishra; Zabrina L Brumme; Stephen Hickling; Christopher S W Tang; Toshiyuki Miura; Chris Seebregts; David Heckerman; Thumbi Ndung'u; Bruce Walker; Paul Klenerman; Dewald Steyn; Philip Goulder; Rodney Phillips; Cloete van Vuuren; John Frater
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

10.  Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients.

Authors:  Paul A Goepfert; Wendy Lumm; Paul Farmer; Philippa Matthews; Andrew Prendergast; Jonathan M Carlson; Cynthia A Derdeyn; Jianming Tang; Richard A Kaslow; Anju Bansal; Karina Yusim; David Heckerman; Joseph Mulenga; Susan Allen; Philip J R Goulder; Eric Hunter
Journal:  J Exp Med       Date:  2008-04-21       Impact factor: 14.307

View more
  18 in total

1.  An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors.

Authors:  Kristof Theys; Pieter J K Libin; Kristel Van Laethem; Ana B Abecasis
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 2.  Clinical and evolutionary consequences of HIV adaptation to HLA: implications for vaccine and cure.

Authors:  Santiago Avila-Rios; Jonathan M Carlson; Mina John; Simon Mallal; Zabrina L Brumme
Journal:  Curr Opin HIV AIDS       Date:  2019-05       Impact factor: 4.283

3.  Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1.

Authors:  Jonathan M Carlson; Chanson J Brumme; Eric Martin; Jennifer Listgarten; Mark A Brockman; Anh Q Le; Celia K S Chui; Laura A Cotton; David J H F Knapp; Sharon A Riddler; Richard Haubrich; George Nelson; Nico Pfeifer; Charles E Deziel; David Heckerman; Richard Apps; Mary Carrington; Simon Mallal; P Richard Harrigan; Mina John; Zabrina L Brumme
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

4.  Comparison of experimental fine-mapping to in silico prediction results of HIV-1 epitopes reveals ongoing need for mapping experiments.

Authors:  Julia Roider; Tim Meissner; Franziska Kraut; Thomas Vollbrecht; Renate Stirner; Johannes R Bogner; Rika Draenert
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

5.  Persistent production of an integrase-deleted HIV-1 variant with no resistance mutation and wild-type proviral DNA in a treated patient.

Authors:  Mary-Anne Trabaud; Laurent Cotte; Julien Saison; Christophe Ramière; Corinne Ronfort; Fabienne Venet; Jean-Claude Tardy; Guillaume Monneret; Patrice André
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

6.  Consequences of HLA-B*13-Associated Escape Mutations on HIV-1 Replication and Nef Function.

Authors:  Aniqa Shahid; Alex Olvera; Gursev Anmole; Xiaomei T Kuang; Laura A Cotton; Montserrat Plana; Christian Brander; Mark A Brockman; Zabrina L Brumme
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

7.  Accumulation of Pol Mutations Selected by HLA-B*52:01-C*12:02 Protective Haplotype-Restricted Cytotoxic T Lymphocytes Causes Low Plasma Viral Load Due to Low Viral Fitness of Mutant Viruses.

Authors:  Hayato Murakoshi; Madoka Koyanagi; Takayuki Chikata; Mohammad Arif Rahman; Nozomi Kuse; Keiko Sakai; Hiroyuki Gatanaga; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

8.  Early evolution of human leucocyte antigen-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C-infected women.

Authors:  Denis R Chopera; Roman Ntale; Nonkululeko Ndabambi; Nigel Garrett; Clive M Gray; David Matten; Quarraisha Abdool Karim; Salim Abdool Karim; Carolyn Williamson
Journal:  AIDS       Date:  2017-01-14       Impact factor: 4.177

9.  Impaired Nef function is associated with early control of HIV-1 viremia.

Authors:  Xiaomei T Kuang; Xiaoguang Li; Gursev Anmole; Philip Mwimanzi; Aniqa Shahid; Anh Q Le; Louise Chong; Hua Qian; Toshiyuki Miura; Tristan Markle; Bemuluyigza Baraki; Elizabeth Connick; Eric S Daar; Heiko Jessen; Anthony D Kelleher; Susan Little; Martin Markowitz; Florencia Pereyra; Eric S Rosenberg; Bruce D Walker; Takamasa Ueno; Zabrina L Brumme; Mark A Brockman
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

10.  Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.

Authors:  Doty B A Ojwach; Daniel MacMillan; Tarylee Reddy; Vladimir Novitsky; Zabrina L Brumme; Mark A Brockman; Thumbi Ndung'u; Jaclyn K Mann
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.